Description: AB Science S.A., a clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France. The company's lead compound is the masitinib, a tyrosine kinase inhibitor which is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis, indolent systemic mastocytosis, severe asthma, progressive forms of multiple sclerosis, first line pancreatic cancer with pain, alzheimer's disease, and metastatic castrate-resistant prostate cancer, as well as in Phase II clinical trial to treat Covid-19. It also developing AB8939, a microtubule destabiliser for acute myeloid leukemia. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.
Home Page: www.ab-science.com
3, avenue George V
Paris,
75008
France
Phone:
33 1 47 20 00 14
Officers
| Name | Title |
|---|---|
| Mr. Alain Moussy MBA | Co-Founder, Chairman, President, CEO, MD & Scientific Director |
| Mr. Laurent Guy MBA | Chief Financial Officer |
| Mr. Christian FASSOTTE | Global Chief Medical Officer |
| Mr. Alexis BERNARD | Head of Veterinary Sales |
| Mr. Harshad KULKARNI | Head of Statistics |
| Dr. Albert Ahn D.V.M. | President of USA Operations |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 47.278 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 40 |